

# Natasha B Leigh

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3951331/natasha-b-leighl-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

294  
papers

19,777  
citations

60  
h-index

137  
g-index

323  
ext. papers

24,609  
ext. citations

4.8  
avg. IF

6.49  
L-index

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 294 | A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry.. <i>Journal of Thoracic Oncology</i> , <b>2022</b> ,                         | 8.9  | 1         |
| 293 | Effects of Ethnicity on Outcomes of Patients With Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection.. <i>JTO Clinical and Research Reports</i> , <b>2022</b> , 3, 100259      | 1.4  | 0         |
| 292 | Factors associated with cognitive impairment and cognitive concerns in patients with metastatic non-small cell lung cancer.. <i>Neuro-Oncology Practice</i> , <b>2022</b> , 9, 50-58                                    | 2.2  |           |
| 291 | Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system.. <i>Cancer Treatment and Research Communications</i> , <b>2022</b> , 31, 100534                             | 2    | 1         |
| 290 | Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data.. <i>Oncologist</i> , <b>2022</b> ,                                    | 5.7  | 1         |
| 289 | End-to-End Non-Small-Cell Lung Cancer Prognostication Using Deep Learning Applied to Pretreatment Computed Tomography. <i>JCO Clinical Cancer Informatics</i> , <b>2021</b> , 5, 1141-1150                              | 5.2  |           |
| 288 | CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2021</b> ,       | 8.9  | 2         |
| 287 | Canadian Consensus Recommendations on the Management of -Altered NSCLC.. <i>Current Oncology</i> , <b>2021</b> , 28, 4552-4576  | 2.8  | 1         |
| 286 | The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211056306   | 5.4  | 1         |
| 285 | Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review. <i>Cancers</i> , <b>2021</b> , 13,  | 6.6  | 1         |
| 284 | Chemical Genetics Screen Identifies COPB2 Tool Compounds That Alters ER Stress Response and Induces RTK Dysregulation in Lung Cancer Cells. <i>Journal of Molecular Biology</i> , <b>2021</b> , 433, 167294             | 6.5  | 2         |
| 283 | Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy.. <i>JTO Clinical and Research Reports</i> , <b>2021</b> , 2, 100251                    | 1.4  | 1         |
| 282 | Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1040-1091                                    | 2.2  | 59        |
| 281 | Minimization of resource utilization data collected within cost-effectiveness analyses conducted alongside Canadian Cancer Trials Group phase III trials. <i>Clinical Trials</i> , <b>2021</b> , 18, 500-504            | 2.2  |           |
| 280 | Automated imaging-based stratification of early-stage lung cancer patients prior to receiving surgical resection using deep learning applied to CTs.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1552-1552 | 2.2  | 1         |
| 279 | Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy. <i>Lung Cancer</i> , <b>2021</b> , 156, 76-81                            | 5.9  | 2         |
| 278 | The effect of prior cancer on non-small cell lung cancer trial eligibility. <i>Cancer Medicine</i> , <b>2021</b> , 10, 4814-4822  | 4.22 | 1         |

|     |   |      |    |
|-----|---|------|----|
| 277 | An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2021</b> , 41, 1-12   | 7.1  | 10 |
| 276 | A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 170-177   | 4.9  | 11 |
| 275 | Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. <i>European Journal of Cancer</i> , <b>2021</b> , 142, 83-91 | 7.5  | 15 |
| 274 | Can Oncologists Predict the Efficacy of Treatments in Randomized Trials?. <i>Oncologist</i> , <b>2021</b> , 26, 56-62   | 5.7  | 4  |
| 273 | The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data. <i>Quality of Life Research</i> , <b>2021</b> , 30, 445-454   | 3.7  | 1  |
| 272 | Lorlatinib in ALK-Rearranged Lung Cancer. <i>Cancer Cell</i> , <b>2021</b> , 39, 25-27  | 24.3 | 2  |
| 271 | Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 190-197  | 21.7 | 14 |
| 270 | Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 253-259  | 4.9  | 17 |
| 269 | Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2117547  | 10.4 | 2  |
| 268 | Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 2040-2050  | 8.9  | 4  |
| 267 | Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3391-3402                                  | 2.2  | 62 |
| 266 | Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760) <b>2021</b> , 9,  |      | 5  |
| 265 | Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare System. <i>Current Oncology</i> , <b>2021</b> , 28, 3268-3279   | 2.8  | 4  |
| 264 | Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 390-407                                 | 4.9  | 1  |
| 263 | Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1368-1377  | 13.4 | 6  |
| 262 | Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada. <i>Journal of Thoracic Disease</i> , <b>2021</b> , 13, 5419-5429   | 2.6  | 1  |
| 261 | Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 1647-1662  | 8.9  | 48 |
| 260 | The financial impact of cancer care on renal cancer patients. <i>Canadian Journal of Urology</i> , <b>2021</b> , 28, 10762-10767  |      |    |

|     |   |      |     |
|-----|---|------|-----|
| 259 | Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.. <i>Current Oncology</i> , <b>2021</b> , 28, 5278-5294                       | 2.8  | 1   |
| 258 | Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients. <i>Lung Cancer</i> , <b>2020</b> , 150, 159-163   | 5.9  | 10  |
| 257 | TERAVOLT: Thoracic Cancers International COVID-19 Collaboration. <i>Cancer Cell</i> , <b>2020</b> , 37, 742-745   | 24.3 | 38  |
| 256 | Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories.. <i>JCO Precision Oncology</i> , <b>2020</b> , 4, 520-533   | 3.6  | 4   |
| 255 | BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. <i>Lung Cancer</i> , <b>2020</b> , 146, 78-85                                      | 5.9  | 6   |
| 254 | ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases. <i>Lung Cancer</i> , <b>2020</b> , 146, 350-354   | 5.9  | 5   |
| 253 | Death Anxiety in Patients With Metastatic Non-Small Cell Lung Cancer With and Without Brain Metastases. <i>Journal of Pain and Symptom Management</i> , <b>2020</b> , 60, 422-429.e1  | 4.8  | 7   |
| 252 | Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study. <i>CMAJ Open</i> , <b>2020</b> , 8, E191-E198  | 2.5  | 8   |
| 251 | Advancing the systemic therapy of lung cancer: quality or quantity?. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 322-324  | 32.4 | 1   |
| 250 | Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. <i>Lancet Respiratory Medicine, the</i> , <b>2020</b> , 8, 561-572                                 | 35.1 | 26  |
| 249 | A drug discovery platform to identify compounds that inhibit EGFR triple mutants. <i>Nature Chemical Biology</i> , <b>2020</b> , 16, 577-586  | 11.7 | 15  |
| 248 | Cancer patients' experiences with immune checkpoint modulators: A qualitative study. <i>Cancer Medicine</i> , <b>2020</b> , 9, 3015-3022  | 4.8  | 6   |
| 247 | Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1608-1632   | 2.2  | 129 |
| 246 | Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 85, 101979  | 14.4 | 14  |
| 245 | Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, e488-e492  | 4.9  | 2   |
| 244 | TCR clonality and Treg frequency as predictors of outcome in stage III NSCLC treated with durvalumab.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3050-3050  | 2.2  | 0   |
| 243 | Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , <b>2020</b> , 126, 1550-1558 | 6.4  | 9   |
| 242 | Value assessment of oncology drugs using a weighted criterion-based approach. <i>Cancer</i> , <b>2020</b> , 126, 1530-1540  | 15.4 | 7   |

|     |   |      |     |
|-----|---|------|-----|
| 241 | Neurological Death is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer Diagnosed With Brain Metastases. <i>Advances in Radiation Oncology</i> , <b>2020</b> , 5, 350-357  | 3.3  | 5   |
| 240 | Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. <i>European Journal of Cancer</i> , <b>2020</b> , 125, 49-57              | 7.5  | 23  |
| 239 | Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 404-415                             | 8.9  | 53  |
| 238 | Defining the role of adjuvant therapy for early-stage large cell neuroendocrine carcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2020</b> , 159, 2043-2054.e9  | 1.5  | 7   |
| 237 | Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERA-VOLT Experience. <i>Cancer Cell</i> , <b>2020</b> , 38, 602-604   | 24.3 | 5   |
| 236 | Mechanisms of osimertinib resistance and emerging treatment options. <i>Lung Cancer</i> , <b>2020</b> , 147, 123-129  | 5.9  | 37  |
| 235 | Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , <b>2020</b> , 12, 2706-2712            | 2.6  | 2   |
| 234 | Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. <i>Lancet Oncology</i> , <b>2020</b> , 21, 1589-1601                         | 21.7 | 26  |
| 233 | Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer. <i>Oncologist</i> , <b>2020</b> , 25, 981-992   | 5.7  | 9   |
| 232 | Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3863-3873                                 | 2.2  | 40  |
| 231 | Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario. <i>Journal of Oncology Pharmacy Practice</i> , <b>2020</b> , 26, 379-385                              | 1.7  | 0   |
| 230 | Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. <i>Oncologist</i> , <b>2020</b> , 25, 64-77  | 5.7  | 22  |
| 229 | Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer. <i>Cancer Medicine</i> , <b>2019</b> , 8, 7542-7555            | 4.8  | 6   |
| 228 | Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2518-2527    | 2.2  | 424 |
| 227 | Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. <i>Lung Cancer</i> , <b>2019</b> , 134, 259-267   | 5.9  | 19  |
| 226 | Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development. <i>Oncotarget</i> , <b>2019</b> , 10, 1760-1774  | 3.3  | 12  |
| 225 | Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4691-4700 | 12.0 | 233 |
| 224 | The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance. <i>Lung Cancer</i> , <b>2019</b> , 131, 86-89  | 5.9  | 9   |

|     |  |      |    |
|-----|--|------|----|
| 223 | Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 347-357  | 35.1 | 88 |
| 222 | Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, 231-236  | 4.9  | 21 |
| 221 | Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing. <i>Cancer</i> , <b>2019</b> , 125, 4043-4051   | 6.4  | 9  |
| 220 | Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis. <i>Molecular Carcinogenesis</i> , <b>2019</b> , 58, 1960-1973   | 5    | 0  |
| 219 | Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2019</b> , 28, 1228-1237   | 4    | 5  |
| 218 | Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153). <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 1428-1438 | 8.9  | 87 |
| 217 | Improving the Management of Brain Metastases in Oncogene-Addicted Non-Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , <b>2019</b> , 15, 571-572  | 3.1  |    |
| 216 | Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz071  | 4.6  | 2  |
| 215 | The Value of Biomarkers in Optimizing the Use of Immuno-oncologic Therapy. <i>Current Drug Targets</i> , <b>2019</b> , 20, 81-86   | 3    | 2  |
| 214 | The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , <b>2019</b> , 20, 21  | 5.4  | 16 |
| 213 | Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , <b>2019</b> , 125, 1341-1349   | 6.4  | 78 |
| 212 | The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis. <i>Oncologist</i> , <b>2019</b> , 24, e501-e509  | 5.7  | 4  |
| 211 | Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma. <i>Oncologist</i> , <b>2019</b> , 24, e510-e517   | 5.7  | 7  |
| 210 | A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. <i>ESMO Open</i> , <b>2019</b> , 4, e000532   | 6    | 5  |
| 209 | Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, e338-e345   | 4.9  | 7  |
| 208 | The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective. <i>Cancer Cytopathology</i> , <b>2019</b> , 127, 72-78   | 3.9  | 5  |
| 207 | Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. <i>Carcinogenesis</i> , <b>2018</b> , 39, 336-346   | 4.6  | 11 |
| 206 | Translation of Knowledge to Practice-Improving Awareness in NSCLC Molecular Testing. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1004-1011   | 8.9  | 4  |

|     |   |      |      |
|-----|---|------|------|
| 205 | Radical Treatment of Stage II Non-small-cell Lung Cancer With Nonsurgical Approaches: A Multi-institution Report of Outcomes. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e11-e18   | 4.9  | 4    |
| 204 | Chemotherapy and radiation treatment decision-making experiences of older adults with cancer: A qualitative study. <i>Journal of Geriatric Oncology</i> , <b>2018</b> , 9, 47-52  | 3.6  | 19   |
| 203 | The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer. <i>Lung Cancer</i> , <b>2018</b> , 123, 22-29   | 5.9  | 13   |
| 202 | Additional germline findings from a tumor profiling program. <i>BMC Medical Genomics</i> , <b>2018</b> , 11, 65   | 3.7  | 12   |
| 201 | Lung cancer in never smokers from the Princess Margaret Cancer Centre. <i>Oncotarget</i> , <b>2018</b> , 9, 22559-22570   | 5.7  | 14   |
| 200 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1714-1768  | 2.2  | 1740 |
| 199 | Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 911-919 | 2.2  | 252  |
| 198 | CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , JCO2018783118  | 2.2  | 284  |
| 197 | Sensitive tumour detection and classification using plasma cell-free DNA methylomes. <i>Nature</i> , <b>2018</b> , 563, 579-583   | 50.4 | 344  |
| 196 | Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. <i>CNS Drugs</i> , <b>2018</b> , 32, 527-542   | 6.7  | 9    |
| 195 | Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, 426-434.e1  | 4.9  | 64   |
| 194 | Rationale and Protocol for a Canadian Multicenter Phase II Randomized Trial Assessing Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-small-cell Lung Cancer (NCT02788461). <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e699-e703  | 4.9  | 10   |
| 193 | ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 156-161   | 4.9  | 56   |
| 192 | Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 388-395.e4  | 4.9  | 19   |
| 191 | Evolution of Symptom Burden of Advanced Lung Cancer Over a Decade. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 274-280.e6   | 4.9  | 40   |
| 190 | Indications for Adjuvant Mediastinal Radiotherapy in Surgically Resected Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , <b>2017</b> , 103, 1647-1653   | 2.7  | 17   |
| 189 | The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1210-1222  | 8.9  | 73   |
| 188 | Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1183-1209  | 8.9  | 29   |

|     |  |      |     |
|-----|--|------|-----|
| 187 | Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature Genetics</i> , <b>2017</b> , 49, 1126-1132   | 36.3 | 246 |
| 186 | Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , <b>2017</b> , 9, 405-414                         | 5.4  | 22  |
| 185 | P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, S1167-S1169   | 8.9  | 9   |
| 184 | Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 123, 195-202   | 5.3  | 32  |
| 183 | Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma. <i>European Respiratory Journal</i> , <b>2017</b> , 49,  | 13.6 | 21  |
| 182 | A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 556-566  | 8.9  | 30  |
| 181 | Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. <i>Lancet Oncology</i> , <b>2017</b> , 18, 1523-1531  | 21.7 | 93  |
| 180 | Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients. <i>Journal of Oncology Practice</i> , <b>2017</b> , 13, 780-783  | 3.1  | 1   |
| 179 | Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3484-3515  | 2.2  | 358 |
| 178 | Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2490-2498                                    | 2.2  | 366 |
| 177 | Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2764-2771 | 2.2  | 44  |
| 176 | Curing Early-Stage Lung Cancer: Is There an Easy Way Out?. <i>Journal of Oncology Practice</i> , <b>2017</b> , 13, 63-65   | 3.1  | 1   |
| 175 | Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. <i>Pharmacoeconomics</i> , <b>2017</b> , 35, 1195-1209   | 4.4  | 14  |
| 174 | Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2017</b> , 18, 1610-1623                                      | 21.7 | 95  |
| 173 | Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , <b>2017</b> , 111, 23-29  | 5.9  | 105 |
| 172 | Chemotherapy treatment decision-making experiences of older adults with cancer, their family members, oncologists and family physicians: a mixed methods study. <i>Supportive Care in Cancer</i> , <b>2017</b> , 25, 879-886                                     | 3.9  | 20  |
| 171 | A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, e41-e47   | 4.9  | 2   |
| 170 | BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2460-2470  | 12.9 | 7   |



|     |   |      |     |
|-----|---|------|-----|
| 169 | Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. <i>Oncologist</i> , <b>2017</b> , 22, 70-80  | 5.7  | 41  |
| 168 | Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 50   | 5.3  | 21  |
| 167 | Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 113   | 5.3  | 38  |
| 166 | Health utility scores (HUS) and health-related quality of life (HRQoL) in stage 4 lung cancer (S4LC) patients with brain metastases (BM).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 24-24  | 2.2  | 1   |
| 165 | Biomarker analysis of the phase 3 TORCH trial for first line erlotinib chemotherapy in advanced non-small cell lung cancer patients. <i>Oncotarget</i> , <b>2017</b> , 8, 57528-57536   | 3.3  | 7   |
| 164 | A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. <i>Oncotarget</i> , <b>2017</b> , 8, 69651-69662   | 3.3  | 20  |
| 163 | Feasibility of collecting routine information for clinical and research purposes via electronic format questionnaire.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 167-167  | 2.2  |     |
| 162 | Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. <i>Oncologist</i> , <b>2016</b> , 21, 1450-1460   | 5.7  | 70  |
| 161 | Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , <b>2016</b> , 8, 109  | 14.4 | 149 |
| 160 | The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy. <i>European Journal of Cancer</i> , <b>2016</b> , 61, 85-93  | 7.5  | 2   |
| 159 | Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 810-5 | 2.2  | 61  |
| 158 | Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2016</b> , 151, 468-73   | 1.5  | 107 |
| 157 | Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions. <i>Future Oncology</i> , <b>2016</b> , 12, 9-23  | 3.6  | 11  |
| 156 | The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 45, 139-62  | 14.4 | 114 |
| 155 | Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1676-88   | 2.2  | 64  |
| 154 | Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2016</b> , 17, 133-41  | 4.9  | 5   |
| 153 | Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 900-9   | 8.9  | 20  |
| 152 | Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 616-22   | 8.7  | 14  |

|     |  |     |     |
|-----|--|-----|-----|
| 151 | Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. <i>ESMO Open</i> , <b>2016</b> , 1, e000118  | 6   | 4   |
| 150 | Incidental germline findings identified in a somatic genomic sequencing program for advanced cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1532-1532   | 2.2 | 2   |
| 149 | E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC Outcomes based on chemotherapy subsets.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 8507-8507  | 2.2 | 13  |
| 148 | Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9007-9007 | 2.2 | 21  |
| 147 | Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9026-9026  | 2.2 | 25  |
| 146 | Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9044-9044              | 2.2 | 26  |
| 145 | Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e20522-e20522               | 2.2 | 5   |
| 144 | A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 25632-9  | 3.3 | 6   |
| 143 | Quality of life (QoL) for FDA-approved agents in advanced NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e18117-e18117  | 2.2 |     |
| 142 | A Phase I/Ib study of MEK162 (binimetinib), a MEK inhibitor, in combination with carboplatin and pemetrexed in patients with non-squamous NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS2609-TPS2609  | 2.2 | 2   |
| 141 | The economic impact of the transition from branded to generic oncology drugs.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 6520-6520   | 2.2 |     |
| 140 | Real-world EQ5D health utility values for metastatic lung cancer patients by molecular alteration and response to therapy.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 6567-6567  | 2.2 |     |
| 139 | Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives. <i>Translational Lung Cancer Research</i> , <b>2016</b> , 5, 628-636  | 4.4 | 12  |
| 138 | How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment. <i>BMJ Open</i> , <b>2016</b> , 6, e010981   | 3   | 18  |
| 137 | Patients with Advanced Non-Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 79-84   | 8.9 | 37  |
| 136 | ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients. <i>Cancer Epidemiology</i> , <b>2016</b> , 41, 50-6                        | 2.8 | 5   |
| 135 | Perceptions of palliative care among patients with advanced cancer and their caregivers. <i>Cmaj</i> , <b>2016</b> , 188, E217-E227  | 3.5 | 175 |
| 134 | P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, S241-S242   | 8.9 | 17  |

|     |  |      |      |
|-----|--|------|------|
| 133 | Early Palliative Care and Its Role in Oncology: A Qualitative Study. <i>Oncologist</i> , <b>2016</b> , 21, 1387-1395   | 5.7  | 24   |
| 132 | Reply to G. Spitzer and M.A. Socinski. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 525-6   | 2.2  |      |
| 131 | The value of personalizing medicine: medical oncologists' views on gene expression profiling in breast cancer treatment. <i>Oncologist</i> , <b>2015</b> , 20, 351-6   | 5.7  | 23   |
| 130 | Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3199-212  | 2.2  | 488  |
| 129 | Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2472-80  | 2.2  | 76   |
| 128 | A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2015</b> , 16, 457-65   | 4.9  | 27   |
| 127 | Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1415-21  | 10.3 | 129  |
| 126 | Correlation of dosimetric and clinical factors with the development of esophagitis and radiation pneumonitis in patients with limited-stage small-cell lung carcinoma. <i>Clinical Lung Cancer</i> , <b>2015</b> , 16, 216-20  | 4.9  | 21   |
| 125 | Pembrolizumab for the treatment of non-small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 2018-28   | 59.2 | 3943 |
| 124 | Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: american society of clinical oncology endorsement of the college of american pathologists/international association for the study of lung cancer/association for molecular pathology guideline. <i>Journal of Oncology Practice</i> , <b>2015</b> , 11, 135-6 | 3.1  | 16   |
| 123 | Central Nervous System Pseudoprogression in a Patient Treated with PD-1 Checkpoint Inhibitor. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, e100-1   | 8.9  | 27   |
| 122 | Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?. <i>Cancer</i> , <b>2015</b> , 121, 2562-9   | 6.4  | 56   |
| 121 | Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review. <i>PLoS ONE</i> , <b>2015</b> , 10, e0121211   | 3.7  | 14   |
| 120 | Evan's Syndrome Associated with Pembrolizumab Therapy in Metastatic Non-Small Cell Lung Cancer. <i>Blood</i> , <b>2015</b> , 126, 4543-4543  | 2.2  | 4    |
| 119 | Predictive value of coexisting KRAS and TP53 mutations on response to chemotherapy in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 11060-11060   | 2.2  | 2    |
| 118 | Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. <i>Journal of Thoracic Disease</i> , <b>2015</b> , 7, 1898-906   | 2.6  | 11   |
| 117 | Third-line chemotherapy in small-cell lung cancer: an international analysis. <i>Clinical Lung Cancer</i> , <b>2014</b> , 15, 110-8  | 4.9  | 43   |
| 116 | A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium. <i>Clinical Lung Cancer</i> , <b>2014</b> , 15, 52-7  | 4.9  | 21   |

|     |   |      |      |
|-----|---|------|------|
| 115 | Genetic markers of bevacizumab-induced hypertension. <i>Angiogenesis</i> , <b>2014</b> , 17, 685-94   | 10.6 | 22   |
| 114 | Second-line therapy in non-small-cell lung cancer: the DELTA between different genotypes widens. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1874-81  | 2.2  | 8    |
| 113 | Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3673-9 | 2.2  | 213  |
| 112 | Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2014</b> , 15, 1379-88   | 21.7 | 103  |
| 111 | Shifting patterns in the interpretation of phase III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is dropping. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1407-11   | 2.2  | 36   |
| 110 | Long-term outcome after resection of non-small cell lung cancer invading the thoracic inlet. <i>Annals of Thoracic Surgery</i> , <b>2014</b> , 98, 962-7  | 2.7  | 0    |
| 109 | Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. <i>Lancet</i> , <b>2014</b> , 383, 1721-30  | 4.0  | 1015 |
| 108 | A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC). <i>Lung Cancer</i> , <b>2014</b> , 84, 289-94  | 5.9  | 11   |
| 107 | Home care utilization and costs in stage IV lung cancer: a Canadian public payer experience. <i>Lung Cancer Management</i> , <b>2014</b> , 3, 439-442   | 2.6  |      |
| 106 | Targeted therapy for lung cancer: reviewing the cost and its effect on treatment decisions. <i>Lung Cancer Management</i> , <b>2014</b> , 3, 477-489  | 2.6  |      |
| 105 | Developing a service model that integrates palliative care throughout cancer care: the time is now. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3330-6  | 2.2  | 66   |
| 104 | Barriers and challenges to global clinical cancer research. <i>Oncologist</i> , <b>2014</b> , 19, 61-7  | 5.7  | 15   |
| 103 | Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 329   | 5.3  | 30   |
| 102 | Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 258   | 5.3  | 2    |
| 101 | Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 204   | 5.3  | 111  |
| 100 | Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers. <i>Cancer Medicine</i> , <b>2014</b> , 3, 426-33   | 4.8  | 15   |
| 99  | A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the "SMART" approach for resectable malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 397-402   | 8.9  | 104  |
| 98  | Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 1449-58   | 8.9  | 32   |

|    |   |      |    |
|----|---|------|----|
| 97 | Sample features associated with success rates in population-based EGFR mutation testing. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 947-956   | 8.9  | 56 |
| 96 | Reply to C.G. Azzoli et al and C. Chouaid et al. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3578-9   | 2.2  | 1  |
| 95 | Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. <i>Angiogenesis</i> , <b>2014</b> , 17, 909-20  | 10.6 | 36 |
| 94 | Cost-effectiveness analysis comparing conventional versus stereotactic body radiotherapy for surgically ineligible stage I non-small-cell lung cancer. <i>Journal of Oncology Practice</i> , <b>2014</b> , 10, e130-6   | 3.1  | 22 |
| 93 | Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS7612-TPS7612 | 2.2  | 1  |
| 92 | End-of-life home care utilization and costs in patients with advanced colorectal cancer. <i>Journal of Community and Supportive Oncology</i> , <b>2014</b> , 12, 92-8   |      | 6  |
| 91 | Satisfaction with oncology care among patients with advanced cancer and their caregivers. <i>Quality of Life Research</i> , <b>2013</b> , 22, 2341-9  | 3.7  | 28 |
| 90 | Can a computerized format replace a paper form in PRO and HRQL evaluation? Psychometric testing of the computer-assisted LCSS instrument (eLCSS-QL). <i>Supportive Care in Cancer</i> , <b>2013</b> , 21, 165-72  | 3.9  | 25 |
| 89 | Chemoradiotherapy for locoregional recurrence of non-small-cell lung cancer after surgical resection: a retrospective analysis. <i>Clinical Lung Cancer</i> , <b>2013</b> , 14, 200-4   | 4.9  | 23 |
| 88 | A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2013</b> , 14, 19-27  | 4.9  | 34 |
| 87 | A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 72, 747-55  | 3.5  | 12 |
| 86 | Long-term outcome after en bloc resection of non-small-cell lung cancer invading the pulmonary sulcus and spine. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 1538-44   | 8.9  | 25 |
| 85 | Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 1136-41   | 8.9  | 35 |
| 84 | Gefitinib: re-emerging from the shadows. <i>Lung Cancer Management</i> , <b>2013</b> , 2, 423-437   | 2.6  |    |
| 83 | KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 530-42  | 8.9  | 84 |
| 82 | Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC?. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 366-8  | 8.9  | 72 |
| 81 | Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8027-8027  | 2.2  | 17 |
| 80 | Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8028-8028  | 2.2  | 26 |

|    |   |     |    |
|----|---|-----|----|
| 79 | Closing the personalized medicine information gap: HER2 test documentation practice. <i>American Journal of Managed Care</i> , <b>2013</b> , 19, 838-44   | 2.1 | 5  |
| 78 | Willingness of patients to provide biologic samples for pharmacogenomic testing.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 6543-6543   | 2.2 | 1  |
| 77 | A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). <i>Cancer Chemotherapy and Pharmacology</i> , <b>2012</b> , 69, 815-24   | 3.5 | 5  |
| 76 | The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2012</b> , 69, 563-71                                | 3.5 | 14 |
| 75 | Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1830-1844                              | 8.9 | 17 |
| 74 | Locoregional failures following thoracic irradiation in patients with limited-stage small cell lung carcinoma. <i>Radiotherapy and Oncology</i> , <b>2012</b> , 102, 263-7  | 5.3 | 10 |
| 73 | Guidelines for health technologies: specific guidance for oncology products in Canada. <i>Value in Health</i> , <b>2012</b> , 15, 580-5   | 3.3 | 13 |
| 72 | Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer. <i>Hormones and Cancer</i> , <b>2012</b> , 3, 93-100   | 5   | 28 |
| 71 | Impact and feasibility of a comprehensive geriatric assessment in the oncology setting: a pilot study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2012</b> , 35, 322-8   | 2.7 | 70 |
| 70 | Angiogenesis inhibitors in lung cancer: beyond VEGF?. <i>Lung Cancer Management</i> , <b>2012</b> , 1, 7-10   | 2.6 |    |
| 69 | A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7541-7541 | 2.2 | 3  |
| 68 | Cluster-randomized trial of early palliative care for patients with metastatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 9003-9003   | 2.2 | 6  |
| 67 | Single nucleotide polymorphisms (SNPs) of the platinum pharmacogenetic and VEGF pathways: Association with survival of platinum-treated stage IV non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7586-7586                    | 2.2 |    |
| 66 | The effect of two BRM promoter variants on the risk of stage I/II upper aerodigestive tract cancers.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 10522-10522   | 2.2 | 3  |
| 65 | Genetic sequence variant (GSV) in TERT-CLPTM1L (5p15.33 locus) and survival in platinum-treated stage-IV non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1535-1535   | 2.2 |    |
| 64 | Social environment as a predictor of smoking cessation and recidivism in lung cancer survivors.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 9032-9032  | 2.2 |    |
| 63 | Central reporting of human epidermal growth factor receptor-2 (HER2) status and adherence to testing and adjuvant trastuzumab treatment guidelines in Ontario.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 166-166   | 2.2 |    |
| 62 | Cancer patients and physicians preferences for decision making regarding pharmacogenomic testing (PGT).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 13-13  | 2.2 |    |

|    |   |     |     |
|----|---|-----|-----|
| 61 | Developing a comprehensive smoking cessation program in patients with lung cancer: The role of social smoking environments.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 75-75  | 2.2 |     |
| 60 | Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 537-44                                      | 8.9 | 44  |
| 59 | A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 1379-91  | 8.9 | 79  |
| 58 | Classification and toxicities of vascular disrupting agents. <i>Clinical Lung Cancer</i> , <b>2011</b> , 12, 18-25  | 4.9 | 24  |
| 57 | Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. <i>Clinical Lung Cancer</i> , <b>2011</b> , 12, 33-7                                | 4.9 | 15  |
| 56 | Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy. <i>Clinical Lung Cancer</i> , <b>2011</b> , 12, 375-9   | 4.9 | 33  |
| 55 | Determinants of quality of life in patients with advanced cancer. <i>Supportive Care in Cancer</i> , <b>2011</b> , 19, 621-9  | 3.9 | 63  |
| 54 | Enhancing decision making about participation in cancer clinical trials: development of a question prompt list. <i>Supportive Care in Cancer</i> , <b>2011</b> , 19, 1227-38  | 3.9 | 34  |
| 53 | How affordable are targeted therapies in non-small cell lung cancer?. <i>Current Treatment Options in Oncology</i> , <b>2011</b> , 12, 1-11   | 5.4 | 11  |
| 52 | EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. <i>Cancer Cytopathology</i> , <b>2011</b> , 119, 80-91  | 3.9 | 95  |
| 51 | Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2077-84                  | 2.2 | 81  |
| 50 | Targeting the phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin pathway in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, S1805-7   | 8.9 | 3   |
| 49 | Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer. <i>Oncologist</i> , <b>2011</b> , 16, 1307-15  | 5.7 | 21  |
| 48 | Do economic evaluations of targeted therapy provide support for decision makers?. <i>Journal of Oncology Practice</i> , <b>2011</b> , 7, 36s-45s  | 3.1 | 8   |
| 47 | Population-Based Health Care Cost Estimates Related to Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , <b>2011</b> , 118, 2068-2068  | 2.2 |     |
| 46 | Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 49-55 | 2.2 | 206 |
| 45 | A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. <i>Oncologist</i> , <b>2010</b> , 15, 810-8  | 5.7 | 52  |
| 44 | Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3316-22  | 2.2 | 84  |

|    |  |     |      |
|----|--|-----|------|
| 43 | Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 1953-7  | 8.9 | 43   |
| 42 | Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 298-306  | 9.7 | 58   |
| 41 | Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAL). <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 1970-6                                    | 8.9 | 87   |
| 40 | A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 1054-9   | 8.9 | 72   |
| 39 | The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 640-8         | 8.9 | 12   |
| 38 | Targeting vascular endothelial growth factor in lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, S484-6   | 8.9 | 3    |
| 37 | Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma. <i>Cancer</i> , <b>2010</b> , 116, 5694-9  | 6.4 | 39   |
| 36 | Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4268-73 | 2.2 | 29   |
| 35 | Economic evaluation of docetaxel for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2009</b> , 10, 283-90  | 6.9 | 6    |
| 34 | Anticoagulation and bleeding: a pooled analysis of lung cancer trials of the NCIC Clinical Trials Group. <i>Journal of Thoracic Oncology</i> , <b>2009</b> , 4, 586-94   | 8.9 | 16   |
| 33 | Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1413-8  | 2.2 | 204  |
| 32 | Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. <i>Cancer</i> , <b>2009</b> , 115, 5516-25  | 6.4 | 54   |
| 31 | Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 404-10   | 2.2 | 124  |
| 30 | Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAL. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1227-34   | 2.2 | 1207 |
| 29 | Initial treatment strategies and outcomes for multifocal bronchioloalveolar carcinoma. <i>Clinical Lung Cancer</i> , <b>2009</b> , 10, 187-92  | 4.9 | 1    |
| 28 | Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 6229-36   | 2.2 | 77   |
| 27 | A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium. <i>Journal of Thoracic Oncology</i> , <b>2009</b> , 4, 1163-9   | 8.9 | 13   |
| 26 | Improved compliance with adjuvant vinorelbine and cisplatin in non-small cell lung cancer. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2009</b> , 2, 265-71  | 2.7 | 5    |



|    |  |     |     |
|----|--|-----|-----|
| 25 | Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer. <i>Health Expectations</i> , <b>2008</b> , 11, 35-45   | 3.7 | 28  |
| 24 | Gefitinib: a consideration of cost. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2008</b> , 8, 223-32  | 2.2 |     |
| 23 | Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 54-9   | 2.2 | 233 |
| 22 | Induction chemoradiation therapy followed by surgical resection for non-small cell lung cancer (NSCLC) invading the thoracic inlet. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2008</b> , 33, 1129-34   | 3   | 26  |
| 21 | Factors contributing to adjuvant therapy decisions. <i>Journal of Thoracic Oncology</i> , <b>2008</b> , 3, 195-6   | 8.9 | 1   |
| 20 | A Phase 2 study of perifosine in advanced or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 108, 87-92  | 4.4 | 66  |
| 19 | Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2256-61 | 2.2 | 39  |
| 18 | Does intensive follow-up alter outcome in patients with advanced lung cancer?. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, 273-81   | 8.9 | 42  |
| 17 | Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, 39-43  | 8.9 | 38  |
| 16 | Docetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomics. <i>Drugs and Aging</i> , <b>2007</b> , 24, 411-28  | 4.7 | 11  |
| 15 | Venous Thromboembolism and Non-Small Cell Lung Cancer: A Pooled Analysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trials.. <i>Blood</i> , <b>2007</b> , 110, 3995-3995  | 2.2 |     |
| 14 | A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2006</b> , 51, 115-21  | 5.9 | 27  |
| 13 | Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. <i>Lung Cancer</i> , <b>2006</b> , 52, 327-32  | 5.9 | 15  |
| 12 | Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer. <i>Chest</i> , <b>2005</b> , 128, 2933-43  | 5.3 | 67  |
| 11 | Determination of GTI-2040, a novel antisense oligonucleotide, in human plasma by using HPLC combined with solid phase and liquid-liquid extractions. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2005</b> , 829, 45-9   | 3.2 | 18  |
| 10 | Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2831-9   | 2.2 | 135 |
| 9  | Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 1278-88  | 2.2 | 388 |
| 8  | Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2926-36   | 2.2 | 285 |

|   |  |      |     |
|---|--|------|-----|
| 7 | Cancer patient preferences for communication of prognosis in the metastatic setting. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 1721-30   | 2.2  | 351 |
| 6 | Treatment decision aids in advanced cancer: when the goal is not cure and the answer is not clear. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 1759-62   | 2.2  | 41  |
| 5 | A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2003</b> , 5, 107-12 | 4.9  | 11  |
| 4 | Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 2241-7   | 12.9 | 81  |
| 3 | Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 1344-52   | 2.2  | 47  |
| 2 | Cost-effectiveness of chemotherapy in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 3750-1;author reply 3751-2   | 2.2  | 2   |
| 1 | Discussing adjuvant cancer therapy. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 1768-78  | 2.2  | 75  |